Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;26(9):1476-1487.
doi: 10.1038/s41590-025-02231-6. Epub 2025 Aug 12.

A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity

Affiliations

A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity

Martin W LaFleur et al. Nat Immunol. 2025 Sep.

Abstract

In vivo CRISPR screens in CD8+ T cells have previously uncovered targets for cancer immunotherapy; however, a minority of the genome has been individually annotated, suggesting that additional regulators remain to be discovered. Here we assessed 899 genes in CD8+ T cells responding to murine melanoma and identified the E3 ubiquitin ligase STUB1 as a new negative regulator of anti-tumor CD8+ T cell function. We demonstrated that Stub1 knockout CD8+ T cells effectively control tumor growth across multiple murine models. Mechanistically, STUB1 interacts with the adapter protein CHIC2 to regulate cytokine receptor expression in mouse and human CD8+ T cells. Among the regulated cytokine receptors, interleukin-27 receptor α is essential for tumor growth control mediated by Stub1/Chic2 knockout CD8+ T cells. Together, these findings establish the STUB1-CHIC2 complex as a regulator of cytokine receptor expression in CD8+ T cells and provide rationale for inhibiting this pathway to enhance CD8+ T cell-mediated anti-tumor immunity.

PubMed Disclaimer

Conflict of interest statement

Competing interests: A.H.S. has patents or is pending royalties on the PD-1 pathway from Roche and Novartis. M.W.L., L.E.M., I.S.L.S., A.M.L., P.K.S.H., N.M.D. and A.H.S. have a patent on methods for modulating STUB1 for the treatment of cancer. A.H.S. is on the advisory boards for Elpiscience, Monopteros, Corner Therapeutics, Bioentre, Alixia, GlaxoSmithKline, Janssen, Amgen, AltruBio, ImmVue and MabQuest, and receives research funding from Calico Life Sciences LLC and Taiwan Bio. J.G.D. consults for Microsoft Research, Abata Therapeutics, Servier, Maze Therapeutics, BioNTech, Sangamo and Pfizer, consults for and has equity in Tango Therapeutics, serves as a paid scientific advisor to the Laboratory for Genomics Research, is funded in part by GlaxoSmithKline and receives funding support from the Functional Genomics Consortium: AbbVie, Bristol Myers Squibb, Janssen and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. His interests were reviewed and are managed by the Broad Institute in accordance with its conflict-of-interest policies. The other authors declare no competing interests.

References

    1. Wolchok JD et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 369, 122–133 (2013). - PMC - PubMed
    1. Ribas A & Wolchok JD Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018). - PMC - PubMed
    1. Zaretsky JM et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N. Engl. J. Med. 375, 819–829 (2016). - PMC - PubMed
    1. Galon J et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science 313, 1960–1964 (2006). - PubMed
    1. McLane LM, Abdel-Hakeem MS & Wherry EJ CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu. Rev. Immunol. 37, 1–39 (2015). - PubMed

MeSH terms

Substances